GlassScriptPhysician profile
Charles W Stout
NPI 1497756597
$8,807.86
in general payments reported to CMS, 2019-2025
21 companies · $544 in 2025
The $544 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,537 · 2020: $1,041 · 2021: $1,292 · 2022: $853 · 2023: $1,803 · 2024: $738 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,656.96 | 2019-2025 | Rhythmia Mapping System, Watchman Access System, General - Therapies |
| Medtronic Vascular, INC. | $683.22 | 2019-2020 | |
| Abbott Laboratories | $656.40 | 2020-2025 | Ensite, Mitraclip, Viewmate |
| Medtronic, INC. | $469.76 | 2021-2024 | Linq II, Pipeline |
| Sanofi-Aventis U.S. LLC | $302.13 | 2023-2024 | |
| Cardiva Medical, INC. | $150.09 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $147.51 | 2019-2023 | Eliquis |
| Acutus Medical, INC. | $118.68 | 2021 | |
| Biosense Webster, INC. | $107.78 | 2023 | Carto 3, Pentaray Nav |
| Pfizer INC. | $78.39 | 2019-2024 | |
| Depuy Synthes Sales INC. | $66.75 | 2025 | Trufill |
| Novartis Pharmaceuticals Corporation | $66.52 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $63.32 | 2019-2022 | |
| Atricure, INC. | $47.80 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.93 | 2022-2023 | Lifevest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.53 | 2022-2025 | Jardiance |
| Amgen INC. | $30.39 | 2019-2024 | Repatha |
| Abiomed | $28.58 | 2024 | Impella |
| Alnylam Pharmaceuticals INC. | $26.58 | 2023 | Amvuttra |
| Merck Sharp & Dohme LLC | $14.78 | 2024 | Verquvo |
| Kestra Medical Technology Services, INC. | $14.76 | 2023 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.